Lantus Manufacturing and Supply: What the Product Records Show

A pharmacy’s answer about “insulin glargine” may not answer whether it can fill your Lantus prescription. Lantus is Sanofi’s insulin glargine product, supplied at 100 units/mL in a 10 mL vial or 3 mL SoloStar pen. Those presentations should be checked separately.[1] Start with the package or prescription rather than the molecule name alone.

Identify what you actually need

For a pharmacy call, record the brand, proper insulin name, concentration, vial or pen, and National Drug Code (NDC), if available. Add how much usable supply remains and the date you expect it to run out. Use it to make the pharmacy call specific.

Ask the pharmacy to check that exact presentation. If it cannot obtain it, ask whether another location can fill the same prescription and what alternative presentation it can actually order. Keep “available to order,” “expected delivery,” and “physically in stock” separate in your notes. Record when the information was obtained; yesterday’s wholesaler response may need checking again before a transfer.

What the dated supply bulletin says

The following is a snapshot of the ASHP/University of Utah bulletin updated August 31, 2026, checked October 14, 2026. It is not a report of current stock at all locations.[2]

A useful follow-up is: “Does this status apply to my exact package?” A notice about one device should not be expanded into a claim about every presentation bearing the same brand. Likewise, a national bulletin cannot settle whether your pharmacy has a particular package ready today.

Approval records answer a different question

FDA records identify the products. Basaglar, from Eli Lilly, has the proper name insulin glargine and was approved separately from the biosimilar pathway.[3] Rezvoglar, insulin glargine-aglr, is an interchangeable biosimilar supplied as a U-100 3 mL pen.[4]

FDA’s biosimilar list also identifies Semglee, Rezvoglar, and Langlara as referencing Lantus.[5] Langlara’s April 2026 label identifies insulin glargine-aldy, a U-100 prefilled pen, manufactured by Sunshine Lake Pharma and distributed by Lannett. That label alone does not establish launch timing, pharmacy inventory, or interchangeability.[6]

Semglee’s 2021 approval established biosimilarity and interchangeability with Lantus.[10] Rezvoglar also has an interchangeable designation.[4] Ask the pharmacist whether the obtainable product can fill your prescription. A familiar brand name still needs a presentation-level supply check.

What manufacturing evidence can tell you

Recombinant insulin production uses engineered organisms and protein-processing steps. A technical review discusses bacterial and yeast platforms, including production and refolding challenges.[7] This explains why manufacturing involves more than filling containers. It does not provide a map of Sanofi’s current plant allocations, output percentages, or shipments to individual pharmacies.

Company names and approvals therefore help identify a product, but do not resolve a backorder. Treat claims about factory capacity or regional distribution cautiously unless they come with a relevant, dated primary record. Broad technology descriptions cannot reliably predict when your prescription will be filled.

Resolve the refill and the treatment plan

If the exact product is unavailable, bring the pharmacy’s findings to the prescribing team. Ask which available product and presentation they intend you to use, whether a new prescription is needed, and what device instruction and monitoring plan should accompany the change. Insulin regimen changes require close supervision and increased glucose monitoring.[1]

Affordability deserves its own check. A historical production-cost model used ingredient quotations, customs data, and estimated additional costs; it did not measure Sanofi’s actual costs or today’s patient price.[8] Ask for the cost of the exact prescribed package under your coverage. Before ending the call, confirm the next action, who will take it, and when you should follow up if the refill remains unresolved.

Frequently asked questions

›Who manufactures Lantus?

Lantus is a Sanofi product, as identified in its current prescribing information.[1] For a refill problem, use the package’s product and presentation details when contacting the pharmacy; the manufacturer’s name alone does not establish local inventory or delivery timing.

›How is insulin glargine made?

Lantus uses recombinant DNA technology in a nonpathogenic Escherichia coli K12 strain.[1] Insulin production broadly involves engineered cells and subsequent protein processing.[7] These descriptions explain the technology, rather than revealing current factory allocations or the availability of a particular pharmacy package.

›Has there been a Lantus shortage?

Yes. The ASHP bulletin updated August 31, 2026, checked October 14, reported a presentation-specific supply problem.[2] Use the table above for that snapshot, then ask your pharmacy to verify the exact package rather than assuming every Lantus presentation is unavailable.

›What is the difference between Lantus and its biosimilars?

Biosimilars are highly similar to their reference product without clinically meaningful differences in safety, purity, or potency. Semglee received an interchangeable designation referencing Lantus; Rezvoglar is also interchangeable.[10][4] Product identity, device, and actual availability still need checking separately.

›How does Lantus work in the body?

Lantus supplies basal insulin through slower, prolonged absorption. Its blood-concentration profile has no pronounced peak compared with NPH in the label's studies; the duration of action varies between people and within the same person.[1]

›Why is insulin glargine so expensive to make?

Recombinant production and protein processing involve technical challenges.[7] However, manufacturing complexity alone does not explain a patient’s price. A published cost model estimated ingredients and additional expenses; it was neither an audit of Sanofi’s costs nor a current pharmacy price quotation.[8]

›Is there a generic version of Lantus available?

FDA lists biosimilars referencing Lantus, including Semglee, Rezvoglar, and Langlara.[5] Basaglar has a different approval pathway.[3] “Generic” is therefore an imprecise shopping term here. Ask the pharmacist for the exact product name, concentration, presentation, substitution status, and confirmed availability.

›How should Lantus be stored?

Unopened: refrigerate at 2–8°C until expiration, or keep at up to 30°C for 28 days. Opened vials: refrigerated or room temperature, 28 days. Opened SoloStar: room temperature only, never refrigerate, 28 days. Never freeze it; protect it from direct heat and light.[1]

›What happens if the Lantus supply is disrupted?

Contact the pharmacy and prescribing team before your supply runs out. Share your exact product details and remaining supply date. Ask for an obtainable option and a supervised treatment plan; insulin regimen changes need close supervision and additional glucose monitoring.[1]

›How many companies make insulin glargine worldwide?

These sources do not establish an exhaustive worldwide count. Defined U.S. examples include Sanofi, Lilly, Biocon-associated products, and the Sunshine Lake Pharma–Lannett manufacturing/distribution arrangement.[1][3][4][2][6] Counting manufacturers, distributors, brands, and licensed products as though they were identical would produce a misleading total.

›Did COVID-19 affect insulin glargine supply?

WHO's May 2020 survey of 155 countries found disruption of diabetes and diabetes-complication treatment services in 49% of responding countries.[11] That documents care disruption; it does not establish the cause or dates of a Lantus factory shortage. A product-specific history needs contemporaneous supply records.

›What is the Inflation Reduction Act insulin cap?

For covered Part D insulin in 2026, a one-month supply has no deductible; cost-sharing is the lowest of $35, 25% of the applicable maximum fair price, or 25% of the plan-negotiated price. This does not guarantee coverage, stock, or uninsured pricing.[9]

References

Sources checked October 14, 2026.

1. Sanofi: Lantus prescribing information, revised May 2025
2. ASHP/University of Utah: Insulin glargine shortage bulletin, updated August 31, 2026
3. FDA Purple Book: Basaglar
4. FDA Purple Book: Rezvoglar
5. FDA: Biosimilar Product Information
6. FDA: Langlara approved prescribing information, April 2026
7. Baeshen et al.: Cell factories for insulin production, 2014
8. Gotham et al.: Production costs and potential prices for biosimilars of human insulin and insulin analogues, 2018
9. CMS: Contract Year 2026 Medicare Advantage and Part D final rule fact sheet
10. FDA: Approval of the first interchangeable biosimilar insulin product, July 2021
11. WHO: COVID-19 impacts on noncommunicable-disease health services, June 1, 2020